SYM FINANCIAL Corp Takes Position in Becton, Dickinson and Company (NYSE:BDX)

SYM FINANCIAL Corp acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 888 shares of the medical instruments supplier’s stock, valued at approximately $201,000.

Several other hedge funds have also recently added to or reduced their stakes in BDX. Sound Income Strategies LLC lifted its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Tompkins Financial Corp raised its stake in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Birch Capital Management LLC boosted its holdings in Becton, Dickinson and Company by 0.4% in the 3rd quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock valued at $2,838,000 after purchasing an additional 48 shares during the period. Radnor Capital Management LLC grew its position in Becton, Dickinson and Company by 1.7% in the 3rd quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 48 shares during the last quarter. Finally, Wesbanco Bank Inc. increased its holdings in shares of Becton, Dickinson and Company by 1.9% during the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after purchasing an additional 48 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.3 %

Shares of BDX opened at $247.63 on Monday. The company has a market capitalization of $71.82 billion, a P/E ratio of 41.69, a PEG ratio of 1.79 and a beta of 0.39. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $250.91. The business’s 50 day simple moving average is $230.53 and its 200-day simple moving average is $233.83. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the previous year, the firm earned $3.42 earnings per share. The business’s revenue was up 6.9% on a year-over-year basis. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share repurchase plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.68%. Becton, Dickinson and Company’s payout ratio is 70.03%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $185,180.00. Following the transaction, the executive vice president now directly owns 16,201 shares in the company, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roland Goette sold 4,483 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the sale, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock valued at $2,210,716 over the last three months. 0.36% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BDX. Piper Sandler lifted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.